BSE filing, NSE: DBOL. Summary written from the filing by ALFA Finder's alert engine.
Dhampur Bio Organics Ltd: key numbers
- Share price
- ₹126.14
- Market cap
- ₹837.4 Cr
- Revenue (annual)
- ₹2,109 Cr
- Net profit (annual)
- ₹25.18 Cr
- P/E (TTM)
- 10.0×Sector 26.2×
- Promoter holding
- 51.00%+0.22% QoQ
- FII holding
- 0.55%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dhampur Bio Organics Ltd
All →Dhampur Bio Organics Management Change
Dhampur Bio Organics Limited announced the cessation of Mr. Surendra Rai Kapur as Cost Auditor due to his demise, effective October 19, 2026.
Dhampur Bio Organics Partnership
Dhampur Bio Organics entered a technology licensing agreement with Planetary SA to produce Mycoprotein, with future plans for a joint venture and offtake agreement.
- Execution
- 10 years
Dhampur Bio Organics Capacity Expansion
Dhampur Bio Organics Ltd. executed a Technology Licensing Agreement with Planetary SA to produce Mycoprotein in India, introducing a new business segment and revenue stream.
Dhampur Bio Organics Other Announcement
The company submitted the certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Dhampur Bio Organics Management Change
Dhampur Bio Organics has promoted Mr. Pankaj Agarwal and Mr. Vinamra Agarwal to Vice President roles. These leadership changes are effective from October 01, 2026.
Dhampur Bio Organics Promoter Buying: ₹1.04 Cr
Promoter group entity Sonitron Limited acquired 85,000 shares of Dhampur Bio Organics Ltd via open market purchases for an aggregate value of ₹1.04 Crore.
- Value
- ₹1.04 Cr
- Promoter stake change
- +0.13%
Other employee stock options announcements
All →RateGain Travel Technologies Employee Stock Options
RateGain granted 53,021 Stock Appreciation Rights under its SAR Scheme 2022 at ₹800 and ₹862.25 per unit. The grants vest over four years and are exercisable within three years of vesting.
- Execution
- Vesting over 4 years (10% Y1, 20% Y2, 30% Y3, 40% Y4); exercisable within 3 years of vesting
Aye Finance Employee Stock Options
Aye Finance's employee welfare trust transferred 89,501 equity shares to grantees on exercising ESOP options. The share capital remains unchanged, so no new issuance occurs.
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.
OnEMI Technology Solutions Employee Stock Options
OnEMI Technology allotted 69,000 equity shares on exercise of employee stock options under the Kissht ESOP 2022 plan. The shares rank pari passu with existing equity.
Bliss GVS Pharma Employee Stock Options
Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.
Bandhan Bank Employee Stock Options
Bandhan Bank's board granted 32,98,871 stock options under ESOP Series 1 (Tranche 9) at Rs 151.91 per option. The options vest over four years, with each option convertible into one equity share.